Synthetic mRNA Splicing Modulator Compounds with in Vivo Antitumor Activity
journal contributionposted on 26.11.2009 by Chandraiah Lagisetti, Alan Pourpak, Tinopiwa Goronga, Qin Jiang, Xiaoli Cui, Judith Hyle, Jill M. Lahti, Stephan W. Morris, Thomas R. Webb
Any type of content formally published in an academic journal, usually following a peer-review process.
We report our progress on the development of new synthetic anticancer lead compounds that modulate the splicing of mRNA. We also report the synthesis and evaluation of new biologically active ester and carbamate analogues. Further, we describe initial animal studies demonstrating the antitumor efficacy of compound 5 in vivo. Additionally, we report the enantioselective and diastereospecific synthesis of a new 1,3-dioxane series of active analogues. We confirm that compound 5 inhibits the splicing of mRNA in cell-free nuclear extracts and in a cell-based dual-reporter mRNA splicing assay. In summary, we have developed totally synthetic novel spliceosome modulators as therapeutic lead compounds for a number of highly aggressive cancers. Future efforts will be directed toward the more complete optimization of these compounds as potential human therapeutics.